Literature DB >> 3117842

Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

A E Hollsing1, M Granström, M L Vasil, B Wretlind, B Strandvik.   

Abstract

Serum immunoglobulin G to four purified antigens from Pseudomonas aeruginosa, phospholipase C, alkaline protease, exotoxin A, and elastase, were determined in 62 patients with cystic fibrosis by enzyme-linked immunosorbent assay. The patients were followed for 12 to 24 months in a prospective study. Increased titers, i.e., titers more than 2 standard deviations above those of normal controls, were exclusively found in patients chronically colonized with P. aeruginosa and not in patients harboring only Staphylococcus aureus. The frequencies of elevated titers of antibody to the different antigens varied from 100% (phospholipase C) to 58% (alkaline protease and exotoxin A) to 15% (elastase) in the chronically colonized patients. Mean serum titer levels, expressed as multiples of the age-correlated upper normal limit (=1), were significantly higher to phospholipase C in patients with dual colonization with P. aeruginosa and S. aureus than in those colonized only with P. aeruginosa (P less than 0.001). Conversely, the other three antigens showed significantly higher serum antibody titer levels in patients harboring only P. aeruginosa (P less than 0.001). In five patients who became colonized with P. aeruginosa during the study period, serum antibodies to phospholipase C and exotoxin A increased first. Exceptions to the general pattern of antibody responses were found in three patients chronically colonized with Escherichia coli. They showed a delayed enhancement of anti-phospholipase C titers after the chronic P. aeruginosa colonization. Serum titers were not influenced by exacerbations of pulmonary infection or by antimicrobial therapy. The determination of titers of serum antibody to phospholipase C seems to be a valuable indicator of a chronic colonization with P. aeruginosa. The results further suggest that bacterial metabolism and interactions may influence the antibody response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117842      PMCID: PMC269358          DOI: 10.1128/jcm.25.10.1868-1874.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  29 in total

1.  Respiratory studies in children. IX. Relationships between mechanical properties of the lungs, lung volumes and ventilatory capacity in healthy children 7-15 years of age.

Authors:  I ENGSTROM; P KARLBERG; C L SWARTS
Journal:  Acta Paediatr       Date:  1962-01       Impact factor: 2.299

2.  Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis.

Authors:  E Kusoffsky; B Strandvik; S Troell
Journal:  J Pediatr Gastroenterol Nutr       Date:  1983       Impact factor: 2.839

Review 3.  Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.

Authors:  G B Pier
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

Review 4.  Antibiotic use in cystic fibrosis.

Authors:  H W Kelly; C Lovato
Journal:  Drug Intell Clin Pharm       Date:  1984-10

Review 5.  Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal.

Authors:  J D Nelson
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

6.  Avirulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa.

Authors:  M A Luzar; T C Montie
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

7.  Biochemical and genetic studies of iron-regulated (exotoxin A) and phosphate-regulated (hemolysin phospholipase C) virulence factors of Pseudomonas aeruginosa.

Authors:  M L Vasil; R M Berka; G L Gray; O R Pavlovskis
Journal:  Antibiot Chemother (1971)       Date:  1985

8.  Reaction of antibody in sera from cystic fibrosis patients with non-toxic forms of Pseudomonas aeruginosa exotoxin A.

Authors:  K W Klinger; C W Shuster; J Klinger
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 5.103

9.  Enzyme-linked immunosorbent assay for detection of antibodies to Pseudomonas aeruginosa exoproteins.

Authors:  M Granström; B Wretlind; B Markman; O R Pavlovskis; M L Vasil
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 5.103

10.  Relation between antibody response to Pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis.

Authors:  M Granström; A Ericsson; B Strandvik; B Wretlind; O R Pavlovskis; R Berka; M L Vasil
Journal:  Acta Paediatr Scand       Date:  1984-11
View more
  30 in total

1.  Genetic mapping of the structural gene for phospholipase C of Pseudomonas aeruginosa PAO.

Authors:  V Lindgren; R M Ostroff; M L Vasil; B Wretlind
Journal:  J Bacteriol       Date:  1990-02       Impact factor: 3.490

Review 2.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

3.  Cooperation between LepA and PlcH contributes to the in vivo virulence and growth of Pseudomonas aeruginosa in mice.

Authors:  Yutaka Kida; Takashi Shimizu; Koichi Kuwano
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

Review 4.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

5.  Comparing the microbiota of the cystic fibrosis lung and human gut.

Authors:  Geraint B Rogers; Mary P Carroll; Lucas R Hoffman; Alan W Walker; David A Fine; Kenneth D Bruce
Journal:  Gut Microbes       Date:  2010-01-29

6.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

7.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

8.  Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis.

Authors:  T R Anderson; T C Montie; M D Murphy; V P McCarthy
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

10.  Antistaphylococcal antibodies in cystic fibrosis.

Authors:  B Strandvik; A Hollsing; R Möllby; M Granström
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.